Esko Kemppainen

Esko Kemppainen

Auto-generated profile, based on publicly available information

Esko Kemppainen

Celiac Disease Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2020 in The Journal of Biochemistry
Verified
Journal Article
Open access
PDF file
HJHoward T Jacobs
Howard T Jacobs
JGJack George
Jack George
EKEsko Kemppainen
Esko Kemppainen
Mitochondrial functions are often considered purely from the standpoint of catabolism, but in growing cells they are mainly dedicated to anabolic processes, and can have a profound impact on the rate of growth. The Drosophila larva, which increases in body mass ∼200-fold over the course of ∼3 days at 25°C, provides an excellent model to study the underlying regulatory machinery that connects mitochondrial metabolic capacity to growth. In this review, we will focus on several key aspects of this machinery: nutrient sensing, endocrine control of feeding and nutrient mobilization, metabolic signalling, protein synthesis regulation and pathways of steroid biosynthesis and activity. In all these aspects, mitochondria appear to play a crucial role.

26 November 2020 in Expert Review of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
AKAlma Kurki
Alma Kurki
EKEsko Kemppainen
Esko Kemppainen
PLPilvi Laurikka
Pilvi Laurikka
KKKatri Kaukinen
Katri Kaukinen
KLKatri Lindfors
Katri Lindfors
: Celiac disease is characterized by an abnormal immune activation driven by the ingestion of gluten from wheat, barley, and rye. Gluten-specific CD4+ T cells play an important role in disease path...

1 November 2011 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
JOJani Oiva
Jani Oiva
OIOuti Itkonen
Outi Itkonen
RKRiitta Koistinen
Riitta Koistinen
KHKristina Hotakainen
Kristina Hotakainen
WZWangming Zhang
Wangming Zhang
HKHannu Koistinen
Hannu Koistinen
BACKGROUND: Trypsinogen 3 is a minor trypsinogen isoform in the pancreas. In contrast with trypsin 1 and 2, trypsin 3 degrades pancreatic secretory trypsin inhibitor, which may lead to an excess of active trypsin and acute pancreatitis (AP). We developed an immunoassay for trypsinogen 3 and studied whether an assay of serum trypsinogen 3 is of clinical utility in the diagnosis of AP. METHODS: Monoclonal antibodies were generated using recombinant human trypsinogen 3 as the antigen and used to establish a sandwich-type immunoassay. We analyzed serum trypsinogen 3 concentrations in 82 patients with AP and 63 patients with upper abdominal pain (controls). The reference interval was determined using serum samples from 172 apparently healthy individuals. RESULTS: The measuring range of the trypsinogen 3 assay was 1.0–250 μg/L. Intra- and interassay CVs were <11%, and cross-reactivity with other trypsinogen isoenzymes was <0.1%. The median trypsinogen 3 concentration in serum from healthy individuals was <1.0 μg/L, and the upper reference limit was 4.4 μg/L. We observed increased trypsinogen 3 concentrations in patients with mild (median 9.5 μg/L) and severe (15.0 μg/L) AP; in both groups, the concentrations were significantly higher than in controls (median <1.0 μg/L) (P < 0.0001). In ROC analysis, the area under the curve of trypsinogen 3 for separation between AP and controls was 0.90 (P < 0.0001). CONCLUSIONS: We established for the first time a specific immunoassay for trypsinogen 3 using monoclonal antibodies. Patients with AP were found to have increased serum concentrations of trypsinogen 3. The availability of this assay will be useful for studies of the clinical utility of trypsinogen 3.

17 September 2019 in Fly
Verified
Journal Article
Open access
JGJack George
Jack George
TTTea Tuomela
Tea Tuomela
EKEsko Kemppainen
Esko Kemppainen
ANAntti Nurminen
Antti Nurminen
SBSamuel Braun
Samuel Braun
HJHoward T. Jacobs
Howard T. Jacobs
The Drosophila bang-sensitive mutant tko25t, manifesting a global deficiency in oxidative phosphorylation due to a mitochondrial protein synthesis defect, exhibits a pronounced delay in larval development. We previously identified a number of metabolic abnormalities in tko25t larvae, including elevated pyruvate and lactate, and found the larval gut to be a crucial tissue for the regulation of larval growth in the mutant. Here we established that expression of wild-type tko in any of several other tissues of tko25t also partially alleviates developmental delay. The effects appeared to be additive, whilst knockdown of tko in a variety of specific tissues phenocopied tko25t, producing developmental delay and bang-sensitivity. These findings imply the existence of a systemic signal regulating growth in response to mitochondrial dysfunction. Drugs and RNAi-targeted on pyruvate metabolism interacted with tko25t in ways that implicated pyruvate or one of its metabolic derivatives in playing a central role in generating such a signal. RNA-seq revealed that dietary pyruvate-induced changes in transcript representation were mostly non-coherent with those produced by tko25t or high-sugar, consistent with the idea that growth regulation operates primarily at the translational and/or metabolic level.

13 March 2025 in Seminars in Immunology
Verified
Journal Article
Closed access
EKEsko Kemppainen
Esko Kemppainen
OAOlga Albó
Olga Albó
HKHelka Kaunisto
Helka Kaunisto
ESEmilia Siukola
Emilia Siukola
KLKatri Lindfors
Katri Lindfors

31 January 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
Partho SenPartho Sen
Partho Sen
SASyed Bilal Ahmad Andrabi
Syed Bilal Ahmad Andrabi
TBTanja Buchacher
Tanja Buchacher
MKMohd Moin Khan
Mohd Moin Khan
UKUbaid Ullah Kalim
Ubaid Ullah Kalim
Matej OresicMatej Oresic
Matej Oresic
T-cells are sentinels of adaptive cell-mediated immune responses. T-cell activation, proliferation and differentiation involves metabolic reprogramming involving the interplay of genes, proteins and metabolites. Here, we aim to understand the metabolic pathways involved in the activation and functional differentiation of human CD4 + T-cell subsets (Th1, Th2, Th17 and iTregs). We combined genome-scale metabolic modeling, gene expression data, targeted and non-targeted lipidomics experiments, together with in vitro gene knockdown experiments and showed that human CD4 + T-cells undergo specific metabolic changes during activation and functional differentiation. In addition, we identified and confirmed the importance of ceramide and glycosphingolipid synthesis pathways in Th17 differentiation and effector functions. Finally, through in vitro gene knockdown experiments, we substantiated the requirement of serine palmitoyl transferase ( SPT ), a de novo sphingolipid pathway in the expression of proinflammatory cytokine (IL17A and IL17F) by Th17 cells. Our findings may provide a comprehensive resource for identifying CD4 + T-cell-specific targets for their selective manipulation under disease conditions, particularly, diseases characterized by an imbalance of Treg / Th17 cells. Our data also suggest a role for elevated levels of ceramides in conditions comorbid with these diseases, e.g. , obesity and insulin resistance.